Personalized mRNA cancer vaccines are showing promising results in late-stage clinical trials for cancers including melanoma, pancreatic cancer and brain tumors, offering the potential to reduce cancer recurrence and extend remission (6/9).

The vaccines use the same mRNA technology that brought COVID-19 vaccines to market in record time. Researchers are studying the technology as a way to train the immune system to recognize and attack cancer cells.

An estimated 2.1 million new cancer cases will be diagnosed in the United States this year, while an estimated 626,000 people will die from cancer, according to the American Cancer Society.

Moderna and Merck are at the forefront of the research. Their experimental treatment combines a personalized mRNA cancer vaccine with a powerful immunotherapy drug.

How Personalized mRNA Cancer Vaccines Work

Personalized cancer vaccines are made for individual patients. They are designed to train the immune system to recognize tumor-specific markers and attack cancer cells while sparing healthy tissue.

Dr. Ryan Sullivan, director of Cutaneous Medical Oncology at Mass General Brigham Cancer Institute, described personalized cancer vaccines as individualized treatments that teach the immune system to recognize and destroy cancer cells.

"Personalized cancer vaccines are individualized therapies that train a patient's immune system to recognize and kill cancer cells," Sullivan said. "These are very promising results that give hope to patients with melanoma and to the entire field of cancer vaccination."

The vaccine trains the immune system to recognize specific cancer proteins, similar to providing a "wanted poster" that helps the body's defenses identify tumor cells for destruction.

Researchers are developing vaccines for melanoma, lung, breast, pancreatic, prostate, brain and other cancers.

What Clinical Trials Show About mRNA Cancer Vaccines

Research into personalized cancer vaccines has produced encouraging results despite a $500 million reduction in federal support for mRNA technology last year.

The vaccines may reduce the risk of cancer returning by 50%, according to the results reported in the source article.

Three notable mRNA cancer vaccine studies have focused on melanoma, pancreatic cancer and brain cancer. The melanoma study showed a reduced risk of cancer recurrence and spread, while the pancreatic cancer study produced cancer-fighting T cells linked to extended remission.

The brain cancer study showed early signs of activating immune defenses against aggressive tumors.

Melanoma Cancer Vaccine Research Shows Promise

Personalized cancer vaccines are being tested in several clinical trials, Sullivan said.

Patients with melanoma considered at high risk of recurrence received personalized vaccines together with immunotherapy. These patients experienced less cancer spread and fewer cases of recurrence than those who did not receive the vaccine, according to Sullivan.

"These results give hope to patients with melanoma but also the entire field of cancer vaccination," Sullivan said.

One study has kept melanoma at bay for five years.

What Comes Next for mRNA Cancer Vaccines

Researchers have conducted more than 120 clinical trials of mRNA cancer vaccines since the early 2000s, examining their potential against numerous cancer types.

The American Cancer Society says cancer vaccine research is advancing rapidly. Scientists are developing better ways to identify tumor targets, including targets based on mRNA technology, to help the immune system recognize and destroy cancer cells more effectively.

Researchers are also studying combinations of cancer vaccines with other treatments, including checkpoint inhibitor immunotherapy, to strengthen the body's anti-cancer response.

The Cancer Research Institute said, "As exciting as these findings are, there is still much to learn."

Developing and bringing an mRNA cancer vaccine to the public can take 10 to 15 years.

ILLUSTRATION: UNSPLASH

This article was created with AI assistance.

We make every effort to ensure the accuracy of our content, some information may be incorrect or outdated. Please let us know of any corrections at [email protected].